Vol.61 No.6 November 2013

Susceptibilities of 4,080 bacterial strains of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2010

Keizo Yamaguchi¹⁾, Yoshikazu Ishii²⁾, Kazuhiro Tateda²⁾, Chikara Shimizu³⁾, Akira Suwabe⁴⁾, Mitsuo Kaku⁵⁾, Akira Hishinuma⁶⁾, Shigefumi Maesaki⁷⁾, Yoshio Kobayashi⁸⁾, Shigemi Kondo⁹⁾, Tetsuya Matsumoto¹⁰⁾, Morihiro Iwata¹¹⁾, Sayoko Kawakami¹²⁾, Yoshihito Otsuka¹³⁾, Masato Maekawa¹⁴⁾, Tetsuya Yagi¹⁵⁾, Yuka Yamagishi¹⁶⁾, Shinichi Fujita¹⁷⁾, Yukio Hida¹⁸⁾, Kaname Nakatani¹⁹⁾, Satoshi Ichiyama²⁰⁾, Ikuko Fujimoto²¹⁾, Hisashi Kohno²²⁾, Hakuo Takahashi²³⁾, Nobuchika Kusano²⁴⁾, Yukinori Kurokawa²⁵⁾, Yaeko Watanabe²⁶⁾, Kiyoshi Negayama²⁷⁾, Hitoshi Miyamoto²⁸⁾, Makiko Kiyosuke²⁹⁾, Kouichi Mashiba³⁰⁾, Katsunori Yanagihara³¹⁾, Yosuke Aoki³²⁾ and Kazufumi Hiramatsu³³⁾

¹⁾Department of Advanced and Integrated Analysis of Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, Tokyo, Japan
²⁾Department of Microbiology and Infectious Diseases, Toho University School of Medicine
³⁾Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital
⁴⁾Central Clinical Laboratory, Iwate Medical University Hospital
⁵⁾The Department of Clinical Laboratory, Tohoku University Graduate School of Medicine
⁶⁾Department of Infection Control and Clinical Laboratory Medicine, Dokkyo Medical University
⁷⁾Department of Infectious Disease and Infection Control, Saitama Medical University
⁸⁾Department of Laboratory Medicine, Keio University Hospital
⁹⁾Department of Laboratory Medicine, Juntendo University School of Medicine
¹⁰⁾Department of Microbiology, Tokyo Medical University
¹¹⁾Department of Clinical Laboratory, Toho University Omori Medical Center
¹²⁾Department of Infection Control and Prevention, Teikyo University Hospital
¹³⁾Laboratory of Medicine, Kameda Medical Center
¹⁴⁾Department of Laboratory Medicine, Hamamatsu University School of Medicine
¹⁵⁾Center of National and Public University Hospital for Infection Control, Nagoya University Hospital
¹⁶⁾Department of Clinical Infectious Diseases, Aichi Medical University Hospital
¹⁷⁾Department of Infection Control and Prevention, Kanazawa University Hospital
¹⁸⁾Department of Clinical Laboratories, University of Fukui Hospital
¹⁹⁾Central Clinical Laboratories, Mie University Hospital
²⁰⁾Department of Clinical Laboratory Medicine and Infectious Diseases, Kyoto University Graduate School of Medicine
²¹⁾Clinical Laboratory, Nara Medical University Hospital
²²⁾Department of Clinical Laboratory, Tenri Hospital
²³⁾Clinical Sciences and Laboratory Medicine, Kansai Medical University Hirakata Hospital
²⁴⁾Department of Infectious Disease, Okayama University Hospital
²⁵⁾Central Clinical Laboratory, Kawasaki Medical School Hospital
²⁶⁾Department of Laboratory Medicine, Hiroshima Prefectural Hospital
²⁷⁾Department of Clinical Laboratory, Kagawa University Hospital
²⁸⁾Division of Medical Technology, Ehime University Hospital
²⁹⁾Department of Clinical Chemistry and Laboratory Medicine, Kyushu University Hospital
³⁰⁾Department of General Medicine・Department of Clinical Laboratory, Kitakyushu Municipal Medical Center
³¹⁾Laboratory Medicine, Nagasaki University Hospital
³²⁾Division of Infectious Disease and Hospital Epidemiology, Saga University Hospital
³³⁾Clinical Laboratory Center, Oita University Hospital

Abstract

Surveillance of β-lactamase production and susceptibilities to antimicrobial agents including tazobactam/piperacillin(TAZ/PIPC) in 4,080 bacterial strains isolated in 2010 were conducted in Japan. β-Lactamase production was investigated over 90% of the strains of Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, indole-positive Proteus spp., Pseudomonas aeruginosa, Acinetobacter spp. and Bacteroides fragilis group., about 60% of staphylococci and 11.1% of Haemophilus influenzae. An increase of the β-lactamase producers in H. influenzae strains was noted, when compared with previous investigations conducted between 2001 and 2006. Extended spectrum β-lactamase(ESBLs) producing strains in E. coli, K. pneumoniae and P. mirabilis were 17.8%, 3.9% and 12.8%, respectively. Increasing levels of ESBLs producers in E. coli, K. pneumoniae and P. mirabilis were investigated compared with previous investigations. Metallo β-lactamase producers in E. cloacae, P. aeruginosa and Acinetobacter spp. were 2.5%, 1.0% and 3.3%, respectively, and no strain of S. marcescens was detected. Susceptibility of 4,080 strains to TAZ/PIPC based on the criteria of the Clinical and Laboratory Standards Institute were distributed from 80.9% in P. aeruginosa to 100% in methicillin-susceptible S. aureus and coagulase-negative staphylococci, P. mirabilis, Proteus spp. (except for Proteus mirabilis) and H. influenzae including β-lactamase-negative ampicillin-resistant H. influenzae. When compared with those in previous investigations, susceptibility to TAZ/PIPC in this decade was not changed and some species of Enterobacteriaceae tend to be susceptible. From these results, TAZ/PIPC is considered as a useful initial therapeutic antimicrobial agent for the infectious diseases reported in various therapeutic guidelines.

Key word

tazobactam/piperacillin, β-lactamase, susceptibility

Received

August 22, 2013

Accepted

September 2, 2013

Jpn. J. Chemother. 61 (6): 514-525, 2013